Today, clinicians announce promising results from an early-stage clinical trial, which tested out a potential new ovarian cancer drug.
A team from the Institute of Cancer Research and Royal Marsden NHS Foundation Trust will present the results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago.
The drug, ONX-0801, is the first in a new series of drugs and attacks ovarian cancer by mimicking folic acid to enter cancer cells. It has been tested in a small phase I trial, a type of trial run in patients with advanced cancer as a way of testing a cancer drug's safety. The drug was shown to shrink tumours in some of the patients, without major side-effects. As a result, the drug shows "promising" results according to researchers, but the small numbers in the trial mean that more work and further clinical trials will need to be done to assess how effective the drug is.
Annwen Jones, Chief Executive of Target Ovarian Cancer, said: "This study shows promising results, although it is a small sample and at a very early stage of research. With very few effective treatment options for ovarian cancer, an approach that develops new ways of targeting ovarian cancer cells more effectively, and with fewer side effects, is to be welcomed."
Find out more
- Read the story in the Independent
- Read about the research on the ASCO website
- Target Ovarian Cancer funds distinctive, UK-wide ovarian cancer research. Find out more and how to help us continue our work in this area